480 related articles for article (PubMed ID: 33208941)
1. Defining HPV-specific B cell responses in patients with head and neck cancer.
Wieland A; Patel MR; Cardenas MA; Eberhardt CS; Hudson WH; Obeng RC; Griffith CC; Wang X; Chen ZG; Kissick HT; Saba NF; Ahmed R
Nature; 2021 Sep; 597(7875):274-278. PubMed ID: 33208941
[TBL] [Abstract][Full Text] [Related]
2. Functional HPV-specific PD-1
Eberhardt CS; Kissick HT; Patel MR; Cardenas MA; Prokhnevska N; Obeng RC; Nasti TH; Griffith CC; Im SJ; Wang X; Shin DM; Carrington M; Chen ZG; Sidney J; Sette A; Saba NF; Wieland A; Ahmed R
Nature; 2021 Sep; 597(7875):279-284. PubMed ID: 34471285
[TBL] [Abstract][Full Text] [Related]
3. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors.
Wood O; Woo J; Seumois G; Savelyeva N; McCann KJ; Singh D; Jones T; Peel L; Breen MS; Ward M; Garrido Martin E; Sanchez-Elsner T; Thomas G; Vijayanand P; Woelk CH; King E; Ottensmeier C;
Oncotarget; 2016 Aug; 7(35):56781-56797. PubMed ID: 27462861
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas.
Sanchez-Canteli M; Granda-Díaz R; Del Rio-Ibisate N; Allonca E; López-Alvarez F; Agorreta J; Garmendia I; Montuenga LM; García-Pedrero JM; Rodrigo JP
Cancer Immunol Immunother; 2020 Oct; 69(10):2089-2100. PubMed ID: 32448984
[TBL] [Abstract][Full Text] [Related]
5. Does pretreatment seropositivity to human papillomavirus have prognostic significance for head and neck cancers?
Smith EM; Rubenstein LM; Ritchie JM; Lee JH; Haugen TH; Hamsikova E; Turek LP
Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2087-96. PubMed ID: 18708401
[TBL] [Abstract][Full Text] [Related]
6. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer.
Badoual C; Hans S; Merillon N; Van Ryswick C; Ravel P; Benhamouda N; Levionnois E; Nizard M; Si-Mohamed A; Besnier N; Gey A; Rotem-Yehudar R; Pere H; Tran T; Guerin CL; Chauvat A; Dransart E; Alanio C; Albert S; Barry B; Sandoval F; Quintin-Colonna F; Bruneval P; Fridman WH; Lemoine FM; Oudard S; Johannes L; Olive D; Brasnu D; Tartour E
Cancer Res; 2013 Jan; 73(1):128-38. PubMed ID: 23135914
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus seropositivity and risks of head and neck cancer.
Smith EM; Ritchie JM; Pawlita M; Rubenstein LM; Haugen TH; Turek LP; Hamsikova E
Int J Cancer; 2007 Feb; 120(4):825-32. PubMed ID: 17131312
[TBL] [Abstract][Full Text] [Related]
8. CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma.
Nordfors C; Grün N; Tertipis N; Ährlund-Richter A; Haeggblom L; Sivars L; Du J; Nyberg T; Marklund L; Munck-Wikland E; Näsman A; Ramqvist T; Dalianis T
Eur J Cancer; 2013 Jul; 49(11):2522-30. PubMed ID: 23571147
[TBL] [Abstract][Full Text] [Related]
9. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis.
Chen X; Yan B; Lou H; Shen Z; Tong F; Zhai A; Wei L; Zhang F
Mol Immunol; 2018 Apr; 96():28-36. PubMed ID: 29477933
[TBL] [Abstract][Full Text] [Related]
10. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of B lymphocyte infiltration in HPV
Zhang S; Wang B; Ma F; Tong F; Yan B; Liu T; Xie H; Song L; Yu S; Wei L
Cancer Sci; 2021 Apr; 112(4):1402-1416. PubMed ID: 33529452
[TBL] [Abstract][Full Text] [Related]
12. Tumor-infiltrating B cells affect the progression of oropharyngeal squamous cell carcinoma via cell-to-cell interactions with CD8
Hladíková K; Koucký V; Bouček J; Laco J; Grega M; Hodek M; Zábrodský M; Vošmik M; Rozkošová K; Vošmiková H; Čelakovský P; Chrobok V; Ryška A; Špíšek R; Fialová A
J Immunother Cancer; 2019 Oct; 7(1):261. PubMed ID: 31623665
[TBL] [Abstract][Full Text] [Related]
13. Validation of Human Papillomavirus as a Favourable Prognostic Marker and Analysis of CD8
Sivars L; Landin D; Grün N; Vlastos A; Marklund L; Nordemar S; Ramqvist T; Munck-Wikland E; Näsman A; Dalianis T
Anticancer Res; 2017 Feb; 37(2):665-673. PubMed ID: 28179315
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
[TBL] [Abstract][Full Text] [Related]
15. CD8
Masterson L; Lechner M; Loewenbein S; Mohammed H; Davies-Husband C; Fenton T; Sudhoff H; Jani P; Goon P; Sterling J
Eur J Cancer; 2016 Nov; 67():141-151. PubMed ID: 27669501
[TBL] [Abstract][Full Text] [Related]
16. Patterns of antibody responses to nonviral cancer antigens in head and neck squamous cell carcinoma patients differ by human papillomavirus status.
Gangkofner DS; Holzinger D; Schroeder L; Eichmüller SB; Zörnig I; Jäger D; Wichmann G; Dietz A; Broglie MA; Herold-Mende C; Dyckhoff G; Boscolo-Rizzo P; Ezic J; Marienfeld RB; Möller P; Völkel G; Kraus JM; Kestler HA; Brunner C; Schuler PJ; Wigand M; Theodoraki MN; Doescher J; Hoffmann TK; Pawlita M; Butt J; Waterboer T; Laban S
Int J Cancer; 2019 Dec; 145(12):3436-3444. PubMed ID: 31407331
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive analysis of immune cell enrichment in the tumor microenvironment of head and neck squamous cell carcinoma.
Mito I; Takahashi H; Kawabata-Iwakawa R; Ida S; Tada H; Chikamatsu K
Sci Rep; 2021 Aug; 11(1):16134. PubMed ID: 34373557
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: correlation with presence of papillomavirus DNA.
Rosales R; López-Contreras M; Cortes RR
J Med Virol; 2001 Dec; 65(4):736-44. PubMed ID: 11745939
[TBL] [Abstract][Full Text] [Related]
19. Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method.
Bishop JA; Ma XJ; Wang H; Luo Y; Illei PB; Begum S; Taube JM; Koch WM; Westra WH
Am J Surg Pathol; 2012 Dec; 36(12):1874-82. PubMed ID: 23060353
[TBL] [Abstract][Full Text] [Related]
20. A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC).
Chandra J; Woo WP; Finlayson N; Liu HY; McGrath M; Ladwa R; Brauer M; Xu Y; Hanson S; Panizza B; Frazer IH; Porceddu SV
Cancer Immunol Immunother; 2021 Mar; 70(3):743-753. PubMed ID: 32918586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
